nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—PDGFRA—malignant glioma	0.448	1	CbGaD
Dasatinib—Cerebral haematoma—Carmustine—malignant glioma	0.0246	0.194	CcSEcCtD
Dasatinib—CYP1A2—Carmustine—malignant glioma	0.00905	0.569	CbGbCtD
Dasatinib—CYP3A4—Temozolomide—malignant glioma	0.00684	0.43	CbGbCtD
Dasatinib—Conjunctival oedema—Carmustine—malignant glioma	0.00307	0.0242	CcSEcCtD
Dasatinib—Pigmentation disorder—Temozolomide—malignant glioma	0.00247	0.0194	CcSEcCtD
Dasatinib—VIIth nerve paralysis—Carmustine—malignant glioma	0.00208	0.0164	CcSEcCtD
Dasatinib—Haemorrhage intracranial—Temozolomide—malignant glioma	0.00201	0.0158	CcSEcCtD
Dasatinib—Myelosuppression—Carmustine—malignant glioma	0.00182	0.0143	CcSEcCtD
Dasatinib—Lung infiltration—Carmustine—malignant glioma	0.00182	0.0143	CcSEcCtD
Dasatinib—Myelosuppression—Temozolomide—malignant glioma	0.00176	0.0138	CcSEcCtD
Dasatinib—Disorder sight—Temozolomide—malignant glioma	0.00173	0.0136	CcSEcCtD
Dasatinib—Transient ischaemic attack—Temozolomide—malignant glioma	0.00163	0.0128	CcSEcCtD
Dasatinib—Cerebral haemorrhage—Carmustine—malignant glioma	0.00154	0.0121	CcSEcCtD
Dasatinib—Cerebral haemorrhage—Temozolomide—malignant glioma	0.00149	0.0117	CcSEcCtD
Dasatinib—Febrile neutropenia—Carmustine—malignant glioma	0.00142	0.0112	CcSEcCtD
Dasatinib—Visual acuity reduced—Temozolomide—malignant glioma	0.00139	0.0109	CcSEcCtD
Dasatinib—Febrile neutropenia—Temozolomide—malignant glioma	0.00137	0.0108	CcSEcCtD
Dasatinib—Deep vein thrombosis—Temozolomide—malignant glioma	0.00135	0.0107	CcSEcCtD
Dasatinib—Embolism—Temozolomide—malignant glioma	0.00128	0.0101	CcSEcCtD
Dasatinib—Cyst—Carmustine—malignant glioma	0.00128	0.01	CcSEcCtD
Dasatinib—Thrombosis—Carmustine—malignant glioma	0.0012	0.00948	CcSEcCtD
Dasatinib—Interstitial lung disease—Carmustine—malignant glioma	0.0012	0.00948	CcSEcCtD
Dasatinib—Interstitial lung disease—Temozolomide—malignant glioma	0.00116	0.00916	CcSEcCtD
Dasatinib—Vaginal haemorrhage—Temozolomide—malignant glioma	0.00111	0.00876	CcSEcCtD
Dasatinib—Cholestasis—Temozolomide—malignant glioma	0.00108	0.00854	CcSEcCtD
Dasatinib—Coagulopathy—Temozolomide—malignant glioma	0.00106	0.00833	CcSEcCtD
Dasatinib—Petechiae—Temozolomide—malignant glioma	0.001	0.00788	CcSEcCtD
Dasatinib—Pulmonary embolism—Carmustine—malignant glioma	0.000853	0.00671	CcSEcCtD
Dasatinib—Musculoskeletal pain—Temozolomide—malignant glioma	0.000834	0.00656	CcSEcCtD
Dasatinib—Pulmonary embolism—Temozolomide—malignant glioma	0.000824	0.00648	CcSEcCtD
Dasatinib—Skin exfoliation—Carmustine—malignant glioma	0.000814	0.00641	CcSEcCtD
Dasatinib—Neuropathy—Carmustine—malignant glioma	0.0008	0.0063	CcSEcCtD
Dasatinib—Skin exfoliation—Temozolomide—malignant glioma	0.000787	0.00619	CcSEcCtD
Dasatinib—Neuropathy—Temozolomide—malignant glioma	0.000774	0.00609	CcSEcCtD
Dasatinib—Neoplasm—Carmustine—malignant glioma	0.000771	0.00607	CcSEcCtD
Dasatinib—Gynaecomastia—Carmustine—malignant glioma	0.000763	0.006	CcSEcCtD
Dasatinib—Dry eye—Temozolomide—malignant glioma	0.000761	0.00599	CcSEcCtD
Dasatinib—Neoplasm—Temozolomide—malignant glioma	0.000745	0.00586	CcSEcCtD
Dasatinib—Sepsis—Carmustine—malignant glioma	0.00074	0.00582	CcSEcCtD
Dasatinib—Thrombophlebitis—Carmustine—malignant glioma	0.000715	0.00563	CcSEcCtD
Dasatinib—FGR—embryo—malignant glioma	0.000692	0.00521	CbGeAlD
Dasatinib—Thrombophlebitis—Temozolomide—malignant glioma	0.000691	0.00544	CcSEcCtD
Dasatinib—EPHA4—brainstem—malignant glioma	0.00069	0.0052	CbGeAlD
Dasatinib—RIPK2—retina—malignant glioma	0.000689	0.00519	CbGeAlD
Dasatinib—SIK2—central nervous system—malignant glioma	0.00068	0.00512	CbGeAlD
Dasatinib—HCK—telencephalon—malignant glioma	0.000674	0.00508	CbGeAlD
Dasatinib—PKMYT1—central nervous system—malignant glioma	0.000663	0.00499	CbGeAlD
Dasatinib—Amnesia—Carmustine—malignant glioma	0.000659	0.00518	CcSEcCtD
Dasatinib—JAK2—embryo—malignant glioma	0.000654	0.00492	CbGeAlD
Dasatinib—SIK3—midbrain—malignant glioma	0.000651	0.00491	CbGeAlD
Dasatinib—EPHA5—medulla oblongata—malignant glioma	0.000648	0.00488	CbGeAlD
Dasatinib—PKMYT1—cerebellum—malignant glioma	0.000648	0.00488	CbGeAlD
Dasatinib—FYN—embryo—malignant glioma	0.000645	0.00486	CbGeAlD
Dasatinib—Amnesia—Temozolomide—malignant glioma	0.000637	0.00501	CcSEcCtD
Dasatinib—MAPK14—brainstem—malignant glioma	0.000637	0.00479	CbGeAlD
Dasatinib—EPHB2—central nervous system—malignant glioma	0.000632	0.00476	CbGeAlD
Dasatinib—BTK—medulla oblongata—malignant glioma	0.000632	0.00476	CbGeAlD
Dasatinib—SIK1—telencephalon—malignant glioma	0.000619	0.00466	CbGeAlD
Dasatinib—SRMS—central nervous system—malignant glioma	0.000619	0.00466	CbGeAlD
Dasatinib—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000619	0.00487	CcSEcCtD
Dasatinib—EPHA4—telencephalon—malignant glioma	0.000613	0.00461	CbGeAlD
Dasatinib—EPHB1—brain—malignant glioma	0.000611	0.00461	CbGeAlD
Dasatinib—ERBB3—telencephalon—malignant glioma	0.000607	0.00457	CbGeAlD
Dasatinib—EPHA8—central nervous system—malignant glioma	0.000606	0.00457	CbGeAlD
Dasatinib—MAP3K2—telencephalon—malignant glioma	0.000601	0.00453	CbGeAlD
Dasatinib—Face oedema—Carmustine—malignant glioma	0.000597	0.0047	CcSEcCtD
Dasatinib—EPHA8—cerebellum—malignant glioma	0.000593	0.00446	CbGeAlD
Dasatinib—EPHA5—midbrain—malignant glioma	0.000593	0.00446	CbGeAlD
Dasatinib—FYN—brainstem—malignant glioma	0.000591	0.00445	CbGeAlD
Dasatinib—Affect lability—Temozolomide—malignant glioma	0.000589	0.00463	CcSEcCtD
Dasatinib—TESK1—medulla oblongata—malignant glioma	0.000586	0.00441	CbGeAlD
Dasatinib—EPHA5—spinal cord—malignant glioma	0.000578	0.00435	CbGeAlD
Dasatinib—Face oedema—Temozolomide—malignant glioma	0.000577	0.00454	CcSEcCtD
Dasatinib—STK36—medulla oblongata—malignant glioma	0.000576	0.00434	CbGeAlD
Dasatinib—STAT5B—central nervous system—malignant glioma	0.000573	0.00432	CbGeAlD
Dasatinib—PDGFRA—embryo—malignant glioma	0.000571	0.0043	CbGeAlD
Dasatinib—MAPK14—telencephalon—malignant glioma	0.000565	0.00426	CbGeAlD
Dasatinib—BTK—spinal cord—malignant glioma	0.000564	0.00425	CbGeAlD
Dasatinib—Hypokalaemia—Carmustine—malignant glioma	0.000563	0.00443	CcSEcCtD
Dasatinib—STAT5B—cerebellum—malignant glioma	0.00056	0.00422	CbGeAlD
Dasatinib—SRC—embryo—malignant glioma	0.00056	0.00422	CbGeAlD
Dasatinib—Dry skin—Temozolomide—malignant glioma	0.000548	0.00431	CcSEcCtD
Dasatinib—Muscular weakness—Carmustine—malignant glioma	0.000546	0.0043	CcSEcCtD
Dasatinib—Hypokalaemia—Temozolomide—malignant glioma	0.000544	0.00428	CcSEcCtD
Dasatinib—Breast disorder—Temozolomide—malignant glioma	0.00054	0.00425	CcSEcCtD
Dasatinib—SIK2—brain—malignant glioma	0.00054	0.00407	CbGeAlD
Dasatinib—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000539	0.00424	CcSEcCtD
Dasatinib—CSK—medulla oblongata—malignant glioma	0.000537	0.00404	CbGeAlD
Dasatinib—EPHB4—telencephalon—malignant glioma	0.000536	0.00403	CbGeAlD
Dasatinib—TESK1—midbrain—malignant glioma	0.000535	0.00403	CbGeAlD
Dasatinib—Dysphagia—Carmustine—malignant glioma	0.000535	0.00421	CcSEcCtD
Dasatinib—JAK2—telencephalon—malignant glioma	0.000532	0.00401	CbGeAlD
Dasatinib—EPHA3—central nervous system—malignant glioma	0.00053	0.00399	CbGeAlD
Dasatinib—HCK—medulla oblongata—malignant glioma	0.00053	0.00399	CbGeAlD
Dasatinib—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000527	0.00415	CcSEcCtD
Dasatinib—Muscular weakness—Temozolomide—malignant glioma	0.000527	0.00415	CcSEcCtD
Dasatinib—PKMYT1—brain—malignant glioma	0.000526	0.00396	CbGeAlD
Dasatinib—FYN—telencephalon—malignant glioma	0.000524	0.00395	CbGeAlD
Dasatinib—TESK1—spinal cord—malignant glioma	0.000522	0.00393	CbGeAlD
Dasatinib—Abdominal distension—Temozolomide—malignant glioma	0.00052	0.0041	CcSEcCtD
Dasatinib—Dysphagia—Temozolomide—malignant glioma	0.000517	0.00407	CcSEcCtD
Dasatinib—SIK3—central nervous system—malignant glioma	0.000516	0.00388	CbGeAlD
Dasatinib—YES1—retina—malignant glioma	0.000515	0.00388	CbGeAlD
Dasatinib—EPHB3—spinal cord—malignant glioma	0.000514	0.00387	CbGeAlD
Dasatinib—MAP4K5—telencephalon—malignant glioma	0.000513	0.00386	CbGeAlD
Dasatinib—Pancytopenia—Carmustine—malignant glioma	0.000508	0.004	CcSEcCtD
Dasatinib—SIK3—cerebellum—malignant glioma	0.000504	0.0038	CbGeAlD
Dasatinib—CSF1R—embryo—malignant glioma	0.000503	0.00379	CbGeAlD
Dasatinib—EPHB2—brain—malignant glioma	0.000502	0.00378	CbGeAlD
Dasatinib—Neutropenia—Carmustine—malignant glioma	0.0005	0.00394	CcSEcCtD
Dasatinib—RIPK2—medulla oblongata—malignant glioma	0.000498	0.00375	CbGeAlD
Dasatinib—LIMK2—spinal cord—malignant glioma	0.000497	0.00374	CbGeAlD
Dasatinib—SRC—retina—malignant glioma	0.000495	0.00373	CbGeAlD
Dasatinib—STK35—midbrain—malignant glioma	0.000494	0.00372	CbGeAlD
Dasatinib—SRMS—brain—malignant glioma	0.000491	0.0037	CbGeAlD
Dasatinib—Pancytopenia—Temozolomide—malignant glioma	0.000491	0.00386	CcSEcCtD
Dasatinib—CSK—midbrain—malignant glioma	0.00049	0.00369	CbGeAlD
Dasatinib—EPHB6—telencephalon—malignant glioma	0.00049	0.00369	CbGeAlD
Dasatinib—SIK1—medulla oblongata—malignant glioma	0.000486	0.00366	CbGeAlD
Dasatinib—HCK—midbrain—malignant glioma	0.000484	0.00365	CbGeAlD
Dasatinib—Neutropenia—Temozolomide—malignant glioma	0.000483	0.0038	CcSEcCtD
Dasatinib—EPHA4—medulla oblongata—malignant glioma	0.000481	0.00363	CbGeAlD
Dasatinib—EPHA8—brain—malignant glioma	0.000481	0.00363	CbGeAlD
Dasatinib—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00048	0.00378	CcSEcCtD
Dasatinib—Pneumonia—Carmustine—malignant glioma	0.00048	0.00378	CcSEcCtD
Dasatinib—ZAK—central nervous system—malignant glioma	0.000479	0.00361	CbGeAlD
Dasatinib—CSK—spinal cord—malignant glioma	0.000478	0.0036	CbGeAlD
Dasatinib—Pollakiuria—Temozolomide—malignant glioma	0.000478	0.00376	CcSEcCtD
Dasatinib—YES1—telencephalon—malignant glioma	0.000473	0.00357	CbGeAlD
Dasatinib—HCK—spinal cord—malignant glioma	0.000472	0.00356	CbGeAlD
Dasatinib—MAP2K5—brainstem—malignant glioma	0.000472	0.00356	CbGeAlD
Dasatinib—Photosensitivity reaction—Temozolomide—malignant glioma	0.000472	0.00371	CcSEcCtD
Dasatinib—Weight increased—Temozolomide—malignant glioma	0.00047	0.0037	CcSEcCtD
Dasatinib—EPHA5—central nervous system—malignant glioma	0.000469	0.00353	CbGeAlD
Dasatinib—Renal failure—Carmustine—malignant glioma	0.000469	0.00369	CcSEcCtD
Dasatinib—ZAK—cerebellum—malignant glioma	0.000468	0.00353	CbGeAlD
Dasatinib—Weight decreased—Temozolomide—malignant glioma	0.000468	0.00368	CcSEcCtD
Dasatinib—Neuropathy peripheral—Carmustine—malignant glioma	0.000468	0.00368	CcSEcCtD
Dasatinib—LYN—central nervous system—malignant glioma	0.000467	0.00351	CbGeAlD
Dasatinib—Stomatitis—Carmustine—malignant glioma	0.000465	0.00366	CcSEcCtD
Dasatinib—PDGFRA—telencephalon—malignant glioma	0.000464	0.0035	CbGeAlD
Dasatinib—Pneumonia—Temozolomide—malignant glioma	0.000464	0.00365	CcSEcCtD
Dasatinib—Infestation—Temozolomide—malignant glioma	0.000461	0.00363	CcSEcCtD
Dasatinib—Infestation NOS—Temozolomide—malignant glioma	0.000461	0.00363	CcSEcCtD
Dasatinib—MAP3K19—central nervous system—malignant glioma	0.00046	0.00346	CbGeAlD
Dasatinib—BMPR1B—central nervous system—malignant glioma	0.00046	0.00346	CbGeAlD
Dasatinib—EPHA5—cerebellum—malignant glioma	0.000458	0.00345	CbGeAlD
Dasatinib—KIT—embryo—malignant glioma	0.000456	0.00344	CbGeAlD
Dasatinib—SRC—telencephalon—malignant glioma	0.000455	0.00343	CbGeAlD
Dasatinib—STAT5B—brain—malignant glioma	0.000455	0.00343	CbGeAlD
Dasatinib—RIPK2—midbrain—malignant glioma	0.000455	0.00343	CbGeAlD
Dasatinib—Neuropathy peripheral—Temozolomide—malignant glioma	0.000452	0.00356	CcSEcCtD
Dasatinib—TNK2—central nervous system—malignant glioma	0.000451	0.00339	CbGeAlD
Dasatinib—Stomatitis—Temozolomide—malignant glioma	0.000449	0.00354	CcSEcCtD
Dasatinib—BMPR1B—cerebellum—malignant glioma	0.000449	0.00338	CbGeAlD
Dasatinib—PDGFRB—embryo—malignant glioma	0.000446	0.00336	CbGeAlD
Dasatinib—RIPK2—spinal cord—malignant glioma	0.000444	0.00334	CbGeAlD
Dasatinib—TNK2—cerebellum—malignant glioma	0.00044	0.00332	CbGeAlD
Dasatinib—Hepatobiliary disease—Temozolomide—malignant glioma	0.000436	0.00343	CcSEcCtD
Dasatinib—ERBB3—midbrain—malignant glioma	0.000436	0.00328	CbGeAlD
Dasatinib—SIK1—spinal cord—malignant glioma	0.000434	0.00327	CbGeAlD
Dasatinib—Haemoglobin—Carmustine—malignant glioma	0.00043	0.00339	CcSEcCtD
Dasatinib—Haemorrhage—Carmustine—malignant glioma	0.000428	0.00337	CcSEcCtD
Dasatinib—ERBB3—spinal cord—malignant glioma	0.000425	0.0032	CbGeAlD
Dasatinib—TESK1—central nervous system—malignant glioma	0.000424	0.00319	CbGeAlD
Dasatinib—Oedema peripheral—Carmustine—malignant glioma	0.000422	0.00332	CcSEcCtD
Dasatinib—EPHB4—medulla oblongata—malignant glioma	0.000421	0.00317	CbGeAlD
Dasatinib—EPHA3—brain—malignant glioma	0.000421	0.00317	CbGeAlD
Dasatinib—Connective tissue disorder—Carmustine—malignant glioma	0.000421	0.00331	CcSEcCtD
Dasatinib—MAP2K5—telencephalon—malignant glioma	0.000419	0.00316	CbGeAlD
Dasatinib—KIT—brainstem—malignant glioma	0.000418	0.00315	CbGeAlD
Dasatinib—JAK2—medulla oblongata—malignant glioma	0.000418	0.00315	CbGeAlD
Dasatinib—STK36—central nervous system—malignant glioma	0.000417	0.00314	CbGeAlD
Dasatinib—EPHB3—central nervous system—malignant glioma	0.000417	0.00314	CbGeAlD
Dasatinib—Haemoglobin—Temozolomide—malignant glioma	0.000416	0.00327	CcSEcCtD
Dasatinib—TESK1—cerebellum—malignant glioma	0.000414	0.00312	CbGeAlD
Dasatinib—Hepatitis—Temozolomide—malignant glioma	0.000414	0.00326	CcSEcCtD
Dasatinib—Haemorrhage—Temozolomide—malignant glioma	0.000414	0.00326	CcSEcCtD
Dasatinib—Visual impairment—Carmustine—malignant glioma	0.000413	0.00325	CcSEcCtD
Dasatinib—FYN—medulla oblongata—malignant glioma	0.000412	0.0031	CbGeAlD
Dasatinib—SIK3—brain—malignant glioma	0.000409	0.00308	CbGeAlD
Dasatinib—CSF1R—telencephalon—malignant glioma	0.000409	0.00308	CbGeAlD
Dasatinib—Urinary tract disorder—Temozolomide—malignant glioma	0.000409	0.00322	CcSEcCtD
Dasatinib—Oedema peripheral—Temozolomide—malignant glioma	0.000408	0.00321	CcSEcCtD
Dasatinib—EPHB3—cerebellum—malignant glioma	0.000408	0.00307	CbGeAlD
Dasatinib—STK36—cerebellum—malignant glioma	0.000408	0.00307	CbGeAlD
Dasatinib—Connective tissue disorder—Temozolomide—malignant glioma	0.000407	0.0032	CcSEcCtD
Dasatinib—Urethral disorder—Temozolomide—malignant glioma	0.000406	0.00319	CcSEcCtD
Dasatinib—LIMK2—central nervous system—malignant glioma	0.000403	0.00304	CbGeAlD
Dasatinib—MAP4K5—medulla oblongata—malignant glioma	0.000403	0.00303	CbGeAlD
Dasatinib—MAP3K3—medulla oblongata—malignant glioma	0.000403	0.00303	CbGeAlD
Dasatinib—Eye disorder—Carmustine—malignant glioma	0.0004	0.00315	CcSEcCtD
Dasatinib—Visual impairment—Temozolomide—malignant glioma	0.000399	0.00314	CcSEcCtD
Dasatinib—Flushing—Carmustine—malignant glioma	0.000397	0.00313	CcSEcCtD
Dasatinib—ABL1—embryo—malignant glioma	0.000397	0.00299	CbGeAlD
Dasatinib—MAPK14—spinal cord—malignant glioma	0.000396	0.00298	CbGeAlD
Dasatinib—LIMK2—cerebellum—malignant glioma	0.000394	0.00297	CbGeAlD
Dasatinib—Erythema multiforme—Temozolomide—malignant glioma	0.000391	0.00308	CcSEcCtD
Dasatinib—STK35—central nervous system—malignant glioma	0.000391	0.00294	CbGeAlD
Dasatinib—CSK—central nervous system—malignant glioma	0.000388	0.00292	CbGeAlD
Dasatinib—Eye disorder—Temozolomide—malignant glioma	0.000387	0.00304	CcSEcCtD
Dasatinib—Tinnitus—Temozolomide—malignant glioma	0.000386	0.00304	CcSEcCtD
Dasatinib—EPHB6—medulla oblongata—malignant glioma	0.000385	0.0029	CbGeAlD
Dasatinib—EPHB4—midbrain—malignant glioma	0.000385	0.0029	CbGeAlD
Dasatinib—Flushing—Temozolomide—malignant glioma	0.000384	0.00302	CcSEcCtD
Dasatinib—Cardiac disorder—Temozolomide—malignant glioma	0.000384	0.00302	CcSEcCtD
Dasatinib—HCK—central nervous system—malignant glioma	0.000383	0.00289	CbGeAlD
Dasatinib—Arrhythmia—Carmustine—malignant glioma	0.000382	0.00301	CcSEcCtD
Dasatinib—STK35—cerebellum—malignant glioma	0.000382	0.00288	CbGeAlD
Dasatinib—ZAK—brain—malignant glioma	0.000381	0.00287	CbGeAlD
Dasatinib—CSK—cerebellum—malignant glioma	0.000379	0.00286	CbGeAlD
Dasatinib—Alopecia—Carmustine—malignant glioma	0.000378	0.00298	CcSEcCtD
Dasatinib—FYN—midbrain—malignant glioma	0.000377	0.00284	CbGeAlD
Dasatinib—Angiopathy—Temozolomide—malignant glioma	0.000375	0.00295	CcSEcCtD
Dasatinib—EPHB4—spinal cord—malignant glioma	0.000375	0.00283	CbGeAlD
Dasatinib—Mental disorder—Carmustine—malignant glioma	0.000375	0.00295	CcSEcCtD
Dasatinib—Immune system disorder—Temozolomide—malignant glioma	0.000374	0.00294	CcSEcCtD
Dasatinib—Mediastinal disorder—Temozolomide—malignant glioma	0.000373	0.00293	CcSEcCtD
Dasatinib—Malnutrition—Carmustine—malignant glioma	0.000373	0.00293	CcSEcCtD
Dasatinib—Erythema—Carmustine—malignant glioma	0.000373	0.00293	CcSEcCtD
Dasatinib—JAK2—spinal cord—malignant glioma	0.000373	0.00281	CbGeAlD
Dasatinib—EPHA5—brain—malignant glioma	0.000372	0.0028	CbGeAlD
Dasatinib—ABL2—cerebellum—malignant glioma	0.000372	0.0028	CbGeAlD
Dasatinib—YES1—medulla oblongata—malignant glioma	0.000372	0.0028	CbGeAlD
Dasatinib—Chills—Temozolomide—malignant glioma	0.000371	0.00292	CcSEcCtD
Dasatinib—KIT—telencephalon—malignant glioma	0.000371	0.0028	CbGeAlD
Dasatinib—LYN—brain—malignant glioma	0.00037	0.00279	CbGeAlD
Dasatinib—MAP3K3—midbrain—malignant glioma	0.000368	0.00277	CbGeAlD
Dasatinib—MAP4K5—midbrain—malignant glioma	0.000368	0.00277	CbGeAlD
Dasatinib—FYN—spinal cord—malignant glioma	0.000367	0.00277	CbGeAlD
Dasatinib—Alopecia—Temozolomide—malignant glioma	0.000366	0.00288	CcSEcCtD
Dasatinib—BMPR1B—brain—malignant glioma	0.000365	0.00275	CbGeAlD
Dasatinib—MAP3K19—brain—malignant glioma	0.000365	0.00275	CbGeAlD
Dasatinib—ABL1—brainstem—malignant glioma	0.000364	0.00274	CbGeAlD
Dasatinib—BTK—brain—malignant glioma	0.000363	0.00273	CbGeAlD
Dasatinib—PDGFRB—telencephalon—malignant glioma	0.000363	0.00273	CbGeAlD
Dasatinib—Mental disorder—Temozolomide—malignant glioma	0.000362	0.00285	CcSEcCtD
Dasatinib—Erythema—Temozolomide—malignant glioma	0.00036	0.00283	CcSEcCtD
Dasatinib—Malnutrition—Temozolomide—malignant glioma	0.00036	0.00283	CcSEcCtD
Dasatinib—MAP3K3—spinal cord—malignant glioma	0.000359	0.0027	CbGeAlD
Dasatinib—MAP4K5—spinal cord—malignant glioma	0.000359	0.0027	CbGeAlD
Dasatinib—TNK2—brain—malignant glioma	0.000358	0.00269	CbGeAlD
Dasatinib—Dysgeusia—Temozolomide—malignant glioma	0.000353	0.00278	CcSEcCtD
Dasatinib—RIPK2—cerebellum—malignant glioma	0.000352	0.00265	CbGeAlD
Dasatinib—SIK1—central nervous system—malignant glioma	0.000352	0.00265	CbGeAlD
Dasatinib—EPHB6—midbrain—malignant glioma	0.000352	0.00265	CbGeAlD
Dasatinib—ABL1—retina—malignant glioma	0.000351	0.00265	CbGeAlD
Dasatinib—Vision blurred—Carmustine—malignant glioma	0.000351	0.00276	CcSEcCtD
Dasatinib—Tremor—Carmustine—malignant glioma	0.000349	0.00275	CcSEcCtD
Dasatinib—EPHA4—central nervous system—malignant glioma	0.000348	0.00262	CbGeAlD
Dasatinib—ERBB3—central nervous system—malignant glioma	0.000345	0.0026	CbGeAlD
Dasatinib—Anaemia—Carmustine—malignant glioma	0.000344	0.00271	CcSEcCtD
Dasatinib—SIK1—cerebellum—malignant glioma	0.000344	0.00259	CbGeAlD
Dasatinib—EPHB6—spinal cord—malignant glioma	0.000343	0.00258	CbGeAlD
Dasatinib—MAP3K2—central nervous system—malignant glioma	0.000342	0.00257	CbGeAlD
Dasatinib—EPHA4—cerebellum—malignant glioma	0.00034	0.00256	CbGeAlD
Dasatinib—YES1—midbrain—malignant glioma	0.00034	0.00256	CbGeAlD
Dasatinib—Vision blurred—Temozolomide—malignant glioma	0.000339	0.00267	CcSEcCtD
Dasatinib—Tremor—Temozolomide—malignant glioma	0.000337	0.00266	CcSEcCtD
Dasatinib—ERBB3—cerebellum—malignant glioma	0.000337	0.00254	CbGeAlD
Dasatinib—TESK1—brain—malignant glioma	0.000336	0.00253	CbGeAlD
Dasatinib—Ill-defined disorder—Temozolomide—malignant glioma	0.000334	0.00263	CcSEcCtD
Dasatinib—MAP3K2—cerebellum—malignant glioma	0.000334	0.00251	CbGeAlD
Dasatinib—Anaemia—Temozolomide—malignant glioma	0.000333	0.00262	CcSEcCtD
Dasatinib—YES1—spinal cord—malignant glioma	0.000332	0.0025	CbGeAlD
Dasatinib—STK36—brain—malignant glioma	0.000331	0.00249	CbGeAlD
Dasatinib—EPHB3—brain—malignant glioma	0.000331	0.00249	CbGeAlD
Dasatinib—MAP2K5—medulla oblongata—malignant glioma	0.000329	0.00248	CbGeAlD
Dasatinib—PDGFRA—spinal cord—malignant glioma	0.000325	0.00245	CbGeAlD
Dasatinib—Malaise—Temozolomide—malignant glioma	0.000325	0.00256	CcSEcCtD
Dasatinib—Vertigo—Temozolomide—malignant glioma	0.000324	0.00255	CcSEcCtD
Dasatinib—ABL1—telencephalon—malignant glioma	0.000323	0.00243	CbGeAlD
Dasatinib—Convulsion—Carmustine—malignant glioma	0.000323	0.00254	CcSEcCtD
Dasatinib—Hypertension—Carmustine—malignant glioma	0.000322	0.00253	CcSEcCtD
Dasatinib—CSF1R—medulla oblongata—malignant glioma	0.000321	0.00242	CbGeAlD
Dasatinib—MAPK14—central nervous system—malignant glioma	0.000321	0.00242	CbGeAlD
Dasatinib—LIMK2—brain—malignant glioma	0.00032	0.00241	CbGeAlD
Dasatinib—FGR—central nervous system—malignant glioma	0.00032	0.00241	CbGeAlD
Dasatinib—SRC—spinal cord—malignant glioma	0.000319	0.0024	CbGeAlD
Dasatinib—Palpitations—Temozolomide—malignant glioma	0.000318	0.0025	CcSEcCtD
Dasatinib—Myalgia—Carmustine—malignant glioma	0.000317	0.0025	CcSEcCtD
Dasatinib—Chest pain—Carmustine—malignant glioma	0.000317	0.0025	CcSEcCtD
Dasatinib—Anxiety—Carmustine—malignant glioma	0.000316	0.00249	CcSEcCtD
Dasatinib—Cough—Temozolomide—malignant glioma	0.000314	0.00247	CcSEcCtD
Dasatinib—MAPK14—cerebellum—malignant glioma	0.000314	0.00236	CbGeAlD
Dasatinib—Convulsion—Temozolomide—malignant glioma	0.000312	0.00246	CcSEcCtD
Dasatinib—Hypertension—Temozolomide—malignant glioma	0.000311	0.00245	CcSEcCtD
Dasatinib—STK35—brain—malignant glioma	0.00031	0.00234	CbGeAlD
Dasatinib—FMO3—central nervous system—malignant glioma	0.000309	0.00233	CbGeAlD
Dasatinib—CSK—brain—malignant glioma	0.000308	0.00232	CbGeAlD
Dasatinib—Confusional state—Carmustine—malignant glioma	0.000307	0.00241	CcSEcCtD
Dasatinib—Arthralgia—Temozolomide—malignant glioma	0.000307	0.00241	CcSEcCtD
Dasatinib—Myalgia—Temozolomide—malignant glioma	0.000307	0.00241	CcSEcCtD
Dasatinib—Anxiety—Temozolomide—malignant glioma	0.000306	0.0024	CcSEcCtD
Dasatinib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000305	0.0024	CcSEcCtD
Dasatinib—HCK—brain—malignant glioma	0.000304	0.00229	CbGeAlD
Dasatinib—Oedema—Carmustine—malignant glioma	0.000304	0.00239	CcSEcCtD
Dasatinib—Discomfort—Temozolomide—malignant glioma	0.000303	0.00238	CcSEcCtD
Dasatinib—ABL2—brain—malignant glioma	0.000302	0.00228	CbGeAlD
Dasatinib—JAK2—central nervous system—malignant glioma	0.000302	0.00228	CbGeAlD
Dasatinib—Infection—Carmustine—malignant glioma	0.000302	0.00238	CcSEcCtD
Dasatinib—MAP2K5—midbrain—malignant glioma	0.000301	0.00227	CbGeAlD
Dasatinib—EPHA2—central nervous system—malignant glioma	0.000299	0.00225	CbGeAlD
Dasatinib—FYN—central nervous system—malignant glioma	0.000298	0.00225	CbGeAlD
Dasatinib—Thrombocytopenia—Carmustine—malignant glioma	0.000298	0.00234	CcSEcCtD
Dasatinib—EPHB4—cerebellum—malignant glioma	0.000298	0.00224	CbGeAlD
Dasatinib—Tachycardia—Carmustine—malignant glioma	0.000297	0.00234	CcSEcCtD
Dasatinib—Confusional state—Temozolomide—malignant glioma	0.000296	0.00233	CcSEcCtD
Dasatinib—JAK2—cerebellum—malignant glioma	0.000295	0.00223	CbGeAlD
Dasatinib—Oedema—Temozolomide—malignant glioma	0.000294	0.00231	CcSEcCtD
Dasatinib—CSF1R—midbrain—malignant glioma	0.000294	0.00221	CbGeAlD
Dasatinib—MAP2K5—spinal cord—malignant glioma	0.000293	0.00221	CbGeAlD
Dasatinib—Infection—Temozolomide—malignant glioma	0.000292	0.0023	CcSEcCtD
Dasatinib—KIT—medulla oblongata—malignant glioma	0.000292	0.0022	CbGeAlD
Dasatinib—FYN—cerebellum—malignant glioma	0.000291	0.00219	CbGeAlD
Dasatinib—MAP4K5—central nervous system—malignant glioma	0.000291	0.00219	CbGeAlD
Dasatinib—MAP3K3—central nervous system—malignant glioma	0.000291	0.00219	CbGeAlD
Dasatinib—Anorexia—Carmustine—malignant glioma	0.00029	0.00228	CcSEcCtD
Dasatinib—Nervous system disorder—Temozolomide—malignant glioma	0.000288	0.00227	CcSEcCtD
Dasatinib—Thrombocytopenia—Temozolomide—malignant glioma	0.000288	0.00227	CcSEcCtD
Dasatinib—CSF1R—spinal cord—malignant glioma	0.000286	0.00216	CbGeAlD
Dasatinib—RIPK2—brain—malignant glioma	0.000286	0.00215	CbGeAlD
Dasatinib—Skin disorder—Temozolomide—malignant glioma	0.000286	0.00225	CcSEcCtD
Dasatinib—PDGFRB—medulla oblongata—malignant glioma	0.000285	0.00215	CbGeAlD
Dasatinib—MAP4K5—cerebellum—malignant glioma	0.000285	0.00214	CbGeAlD
Dasatinib—MAP3K3—cerebellum—malignant glioma	0.000285	0.00214	CbGeAlD
Dasatinib—Hypotension—Carmustine—malignant glioma	0.000284	0.00224	CcSEcCtD
Dasatinib—Hyperhidrosis—Temozolomide—malignant glioma	0.000284	0.00224	CcSEcCtD
Dasatinib—Anorexia—Temozolomide—malignant glioma	0.00028	0.00221	CcSEcCtD
Dasatinib—SIK1—brain—malignant glioma	0.000279	0.0021	CbGeAlD
Dasatinib—EPHB6—central nervous system—malignant glioma	0.000278	0.0021	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000277	0.00218	CcSEcCtD
Dasatinib—EPHA4—brain—malignant glioma	0.000276	0.00208	CbGeAlD
Dasatinib—Insomnia—Carmustine—malignant glioma	0.000275	0.00217	CcSEcCtD
Dasatinib—ERBB3—brain—malignant glioma	0.000274	0.00206	CbGeAlD
Dasatinib—CYP1B1—telencephalon—malignant glioma	0.000274	0.00206	CbGeAlD
Dasatinib—EPHB6—cerebellum—malignant glioma	0.000272	0.00205	CbGeAlD
Dasatinib—Dyspnoea—Carmustine—malignant glioma	0.000271	0.00213	CcSEcCtD
Dasatinib—MAP3K2—brain—malignant glioma	0.000271	0.00204	CbGeAlD
Dasatinib—Somnolence—Carmustine—malignant glioma	0.00027	0.00213	CcSEcCtD
Dasatinib—YES1—central nervous system—malignant glioma	0.000269	0.00203	CbGeAlD
Dasatinib—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000268	0.00211	CcSEcCtD
Dasatinib—KIT—midbrain—malignant glioma	0.000267	0.00201	CbGeAlD
Dasatinib—Insomnia—Temozolomide—malignant glioma	0.000266	0.00209	CcSEcCtD
Dasatinib—Decreased appetite—Carmustine—malignant glioma	0.000264	0.00208	CcSEcCtD
Dasatinib—PDGFRA—central nervous system—malignant glioma	0.000264	0.00199	CbGeAlD
Dasatinib—YES1—cerebellum—malignant glioma	0.000263	0.00198	CbGeAlD
Dasatinib—Gastrointestinal disorder—Carmustine—malignant glioma	0.000263	0.00207	CcSEcCtD
Dasatinib—Dyspnoea—Temozolomide—malignant glioma	0.000262	0.00206	CcSEcCtD
Dasatinib—Somnolence—Temozolomide—malignant glioma	0.000261	0.00206	CcSEcCtD
Dasatinib—PDGFRB—midbrain—malignant glioma	0.00026	0.00196	CbGeAlD
Dasatinib—Constipation—Carmustine—malignant glioma	0.00026	0.00205	CcSEcCtD
Dasatinib—Pain—Carmustine—malignant glioma	0.00026	0.00205	CcSEcCtD
Dasatinib—KIT—spinal cord—malignant glioma	0.00026	0.00196	CbGeAlD
Dasatinib—SRC—central nervous system—malignant glioma	0.000259	0.00195	CbGeAlD
Dasatinib—Dyspepsia—Temozolomide—malignant glioma	0.000259	0.00204	CcSEcCtD
Dasatinib—PDGFRA—cerebellum—malignant glioma	0.000258	0.00194	CbGeAlD
Dasatinib—Decreased appetite—Temozolomide—malignant glioma	0.000256	0.00201	CcSEcCtD
Dasatinib—MAPK14—brain—malignant glioma	0.000255	0.00192	CbGeAlD
Dasatinib—PDGFRB—spinal cord—malignant glioma	0.000254	0.00191	CbGeAlD
Dasatinib—ABL1—medulla oblongata—malignant glioma	0.000254	0.00191	CbGeAlD
Dasatinib—FGR—brain—malignant glioma	0.000254	0.00191	CbGeAlD
Dasatinib—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000254	0.002	CcSEcCtD
Dasatinib—Fatigue—Temozolomide—malignant glioma	0.000253	0.00199	CcSEcCtD
Dasatinib—SRC—cerebellum—malignant glioma	0.000253	0.00191	CbGeAlD
Dasatinib—Constipation—Temozolomide—malignant glioma	0.000251	0.00198	CcSEcCtD
Dasatinib—Pain—Temozolomide—malignant glioma	0.000251	0.00198	CcSEcCtD
Dasatinib—Feeling abnormal—Carmustine—malignant glioma	0.000251	0.00197	CcSEcCtD
Dasatinib—Gastrointestinal pain—Carmustine—malignant glioma	0.000249	0.00196	CcSEcCtD
Dasatinib—FMO3—brain—malignant glioma	0.000245	0.00185	CbGeAlD
Dasatinib—Feeling abnormal—Temozolomide—malignant glioma	0.000242	0.00191	CcSEcCtD
Dasatinib—EPHB4—brain—malignant glioma	0.000242	0.00182	CbGeAlD
Dasatinib—Abdominal pain—Carmustine—malignant glioma	0.00024	0.00189	CcSEcCtD
Dasatinib—Body temperature increased—Carmustine—malignant glioma	0.00024	0.00189	CcSEcCtD
Dasatinib—Gastrointestinal pain—Temozolomide—malignant glioma	0.00024	0.00189	CcSEcCtD
Dasatinib—JAK2—brain—malignant glioma	0.00024	0.00181	CbGeAlD
Dasatinib—MAP2K5—central nervous system—malignant glioma	0.000238	0.00179	CbGeAlD
Dasatinib—EPHA2—brain—malignant glioma	0.000237	0.00179	CbGeAlD
Dasatinib—FYN—brain—malignant glioma	0.000237	0.00178	CbGeAlD
Dasatinib—Urticaria—Temozolomide—malignant glioma	0.000234	0.00184	CcSEcCtD
Dasatinib—MAP2K5—cerebellum—malignant glioma	0.000233	0.00175	CbGeAlD
Dasatinib—Abdominal pain—Temozolomide—malignant glioma	0.000232	0.00183	CcSEcCtD
Dasatinib—Body temperature increased—Temozolomide—malignant glioma	0.000232	0.00183	CcSEcCtD
Dasatinib—CSF1R—central nervous system—malignant glioma	0.000232	0.00175	CbGeAlD
Dasatinib—ABL1—midbrain—malignant glioma	0.000232	0.00175	CbGeAlD
Dasatinib—MAP3K3—brain—malignant glioma	0.000231	0.00174	CbGeAlD
Dasatinib—MAP4K5—brain—malignant glioma	0.000231	0.00174	CbGeAlD
Dasatinib—CSF1R—cerebellum—malignant glioma	0.000227	0.00171	CbGeAlD
Dasatinib—ABL1—spinal cord—malignant glioma	0.000226	0.00171	CbGeAlD
Dasatinib—Hypersensitivity—Carmustine—malignant glioma	0.000224	0.00176	CcSEcCtD
Dasatinib—EPHB6—brain—malignant glioma	0.000221	0.00166	CbGeAlD
Dasatinib—Asthenia—Carmustine—malignant glioma	0.000218	0.00172	CcSEcCtD
Dasatinib—Hypersensitivity—Temozolomide—malignant glioma	0.000217	0.0017	CcSEcCtD
Dasatinib—YES1—brain—malignant glioma	0.000214	0.00161	CbGeAlD
Dasatinib—KIT—central nervous system—malignant glioma	0.000211	0.00159	CbGeAlD
Dasatinib—Asthenia—Temozolomide—malignant glioma	0.000211	0.00166	CcSEcCtD
Dasatinib—PDGFRA—brain—malignant glioma	0.00021	0.00158	CbGeAlD
Dasatinib—Diarrhoea—Carmustine—malignant glioma	0.000208	0.00164	CcSEcCtD
Dasatinib—Pruritus—Temozolomide—malignant glioma	0.000208	0.00164	CcSEcCtD
Dasatinib—ABCB1—blood vessel—malignant glioma	0.000207	0.00156	CbGeAlD
Dasatinib—KIT—cerebellum—malignant glioma	0.000206	0.00155	CbGeAlD
Dasatinib—PDGFRB—central nervous system—malignant glioma	0.000206	0.00155	CbGeAlD
Dasatinib—SRC—brain—malignant glioma	0.000205	0.00155	CbGeAlD
Dasatinib—ABCG2—telencephalon—malignant glioma	0.000204	0.00153	CbGeAlD
Dasatinib—PDGFRB—cerebellum—malignant glioma	0.000201	0.00152	CbGeAlD
Dasatinib—Dizziness—Carmustine—malignant glioma	0.000201	0.00158	CcSEcCtD
Dasatinib—Diarrhoea—Temozolomide—malignant glioma	0.000201	0.00158	CcSEcCtD
Dasatinib—Dizziness—Temozolomide—malignant glioma	0.000194	0.00153	CcSEcCtD
Dasatinib—Vomiting—Carmustine—malignant glioma	0.000193	0.00152	CcSEcCtD
Dasatinib—Rash—Carmustine—malignant glioma	0.000192	0.00151	CcSEcCtD
Dasatinib—Dermatitis—Carmustine—malignant glioma	0.000192	0.00151	CcSEcCtD
Dasatinib—Headache—Carmustine—malignant glioma	0.000191	0.0015	CcSEcCtD
Dasatinib—MAP2K5—brain—malignant glioma	0.000189	0.00142	CbGeAlD
Dasatinib—Vomiting—Temozolomide—malignant glioma	0.000187	0.00147	CcSEcCtD
Dasatinib—Rash—Temozolomide—malignant glioma	0.000185	0.00146	CcSEcCtD
Dasatinib—Dermatitis—Temozolomide—malignant glioma	0.000185	0.00146	CcSEcCtD
Dasatinib—CSF1R—brain—malignant glioma	0.000184	0.00139	CbGeAlD
Dasatinib—Headache—Temozolomide—malignant glioma	0.000184	0.00145	CcSEcCtD
Dasatinib—ABL1—central nervous system—malignant glioma	0.000184	0.00138	CbGeAlD
Dasatinib—Nausea—Carmustine—malignant glioma	0.000181	0.00142	CcSEcCtD
Dasatinib—ABL1—cerebellum—malignant glioma	0.00018	0.00135	CbGeAlD
Dasatinib—Nausea—Temozolomide—malignant glioma	0.000175	0.00137	CcSEcCtD
Dasatinib—KIT—brain—malignant glioma	0.000168	0.00126	CbGeAlD
Dasatinib—PDGFRB—brain—malignant glioma	0.000164	0.00123	CbGeAlD
Dasatinib—ABCG2—medulla oblongata—malignant glioma	0.00016	0.00121	CbGeAlD
Dasatinib—CYP1B1—central nervous system—malignant glioma	0.000156	0.00117	CbGeAlD
Dasatinib—CYP1B1—cerebellum—malignant glioma	0.000152	0.00115	CbGeAlD
Dasatinib—ABCG2—midbrain—malignant glioma	0.000146	0.0011	CbGeAlD
Dasatinib—ABL1—brain—malignant glioma	0.000146	0.0011	CbGeAlD
Dasatinib—ABCG2—spinal cord—malignant glioma	0.000143	0.00108	CbGeAlD
Dasatinib—ABCB1—embryo—malignant glioma	0.000124	0.000931	CbGeAlD
Dasatinib—CYP1B1—brain—malignant glioma	0.000123	0.00093	CbGeAlD
Dasatinib—ABCG2—cerebellum—malignant glioma	0.000113	0.000853	CbGeAlD
Dasatinib—CYP1A1—central nervous system—malignant glioma	0.00011	0.000828	CbGeAlD
Dasatinib—ABCB1—retina—malignant glioma	0.000109	0.000823	CbGeAlD
Dasatinib—ABCB1—telencephalon—malignant glioma	0.0001	0.000757	CbGeAlD
Dasatinib—ABCG2—brain—malignant glioma	9.2e-05	0.000693	CbGeAlD
Dasatinib—CYP1A1—brain—malignant glioma	8.73e-05	0.000658	CbGeAlD
Dasatinib—CYP3A4—central nervous system—malignant glioma	8.07e-05	0.000608	CbGeAlD
Dasatinib—ABCB1—medulla oblongata—malignant glioma	7.9e-05	0.000595	CbGeAlD
Dasatinib—ABCB1—midbrain—malignant glioma	7.22e-05	0.000544	CbGeAlD
Dasatinib—ABCB1—spinal cord—malignant glioma	7.04e-05	0.00053	CbGeAlD
Dasatinib—ABCB1—central nervous system—malignant glioma	5.71e-05	0.00043	CbGeAlD
Dasatinib—ABCB1—cerebellum—malignant glioma	5.58e-05	0.00042	CbGeAlD
Dasatinib—ABCB1—brain—malignant glioma	4.53e-05	0.000342	CbGeAlD
Dasatinib—FYN—Signaling Pathways—CXCL8—malignant glioma	1.17e-06	4.24e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—PIK3CA—malignant glioma	1.17e-06	4.22e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—EGFR—malignant glioma	1.17e-06	4.22e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTGS2—malignant glioma	1.16e-06	4.21e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CD—malignant glioma	1.16e-06	4.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—CASP3—malignant glioma	1.16e-06	4.21e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—EGFR—malignant glioma	1.16e-06	4.2e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—PIK3CA—malignant glioma	1.16e-06	4.2e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—IL2—malignant glioma	1.16e-06	4.2e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGF—malignant glioma	1.16e-06	4.19e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CB—malignant glioma	1.16e-06	4.19e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—VEGFA—malignant glioma	1.16e-06	4.18e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—malignant glioma	1.16e-06	4.18e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—malignant glioma	1.15e-06	4.18e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—PIK3CA—malignant glioma	1.15e-06	4.17e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTPN11—malignant glioma	1.15e-06	4.16e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—PIK3CA—malignant glioma	1.15e-06	4.16e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—STAT3—malignant glioma	1.15e-06	4.14e-06	CbGpPWpGaD
Dasatinib—KIT—Immune System—AKT1—malignant glioma	1.14e-06	4.13e-06	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—AKT1—malignant glioma	1.14e-06	4.13e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—CAV1—malignant glioma	1.14e-06	4.12e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	1.14e-06	4.12e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—CASP3—malignant glioma	1.14e-06	4.12e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—IL2—malignant glioma	1.14e-06	4.11e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	1.13e-06	4.08e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CXCL8—malignant glioma	1.13e-06	4.08e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—CASP3—malignant glioma	1.12e-06	4.05e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—STAT3—malignant glioma	1.12e-06	4.05e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—IL2—malignant glioma	1.12e-06	4.05e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—NCOR1—malignant glioma	1.12e-06	4.04e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PTEN—malignant glioma	1.12e-06	4.04e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—malignant glioma	1.12e-06	4.03e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—FGF2—malignant glioma	1.11e-06	4.03e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CXCL8—malignant glioma	1.11e-06	4.03e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PTEN—malignant glioma	1.11e-06	4.01e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—PIK3CA—malignant glioma	1.11e-06	4e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—EGFR—malignant glioma	1.1e-06	3.99e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—BRAF—malignant glioma	1.1e-06	3.98e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—malignant glioma	1.1e-06	3.98e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—PIK3CA—malignant glioma	1.1e-06	3.98e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CG—malignant glioma	1.1e-06	3.97e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MMP9—malignant glioma	1.1e-06	3.97e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—malignant glioma	1.1e-06	3.97e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—VEGFA—malignant glioma	1.1e-06	3.96e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PTEN—malignant glioma	1.09e-06	3.95e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—PIK3CA—malignant glioma	1.09e-06	3.95e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	1.09e-06	3.94e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—STAT3—malignant glioma	1.08e-06	3.92e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—AKT1—malignant glioma	1.08e-06	3.91e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTT1—malignant glioma	1.08e-06	3.91e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—CASP3—malignant glioma	1.08e-06	3.9e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—IL2—malignant glioma	1.08e-06	3.9e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MMP9—malignant glioma	1.08e-06	3.89e-06	CbGpPWpGaD
Dasatinib—JAK2—GPCR downstream signaling—AKT1—malignant glioma	1.08e-06	3.89e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—STAT3—malignant glioma	1.07e-06	3.88e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT2—malignant glioma	1.07e-06	3.88e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PTEN—malignant glioma	1.07e-06	3.87e-06	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—AKT1—malignant glioma	1.07e-06	3.86e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—CASP3—malignant glioma	1.07e-06	3.85e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—MYC—malignant glioma	1.06e-06	3.85e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—IL2—malignant glioma	1.06e-06	3.85e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—PIK3CA—malignant glioma	1.06e-06	3.84e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PPARG—malignant glioma	1.06e-06	3.84e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MMP9—malignant glioma	1.06e-06	3.83e-06	CbGpPWpGaD
Dasatinib—KIT—Disease—AKT1—malignant glioma	1.05e-06	3.81e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PTEN—malignant glioma	1.05e-06	3.81e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MDM2—malignant glioma	1.04e-06	3.77e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—EGFR—malignant glioma	1.04e-06	3.77e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—malignant glioma	1.04e-06	3.77e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—MYC—malignant glioma	1.04e-06	3.76e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—RAF1—malignant glioma	1.04e-06	3.76e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CG—malignant glioma	1.04e-06	3.76e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CD—malignant glioma	1.03e-06	3.73e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—ERBB2—malignant glioma	1.03e-06	3.72e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MMP9—malignant glioma	1.02e-06	3.69e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—EGFR—malignant glioma	1.02e-06	3.68e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PTEN—malignant glioma	1.02e-06	3.67e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CB—malignant glioma	1.01e-06	3.67e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PTEN—malignant glioma	1.01e-06	3.67e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS1—malignant glioma	1.01e-06	3.66e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—PIK3CA—malignant glioma	1.01e-06	3.66e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—PIK3CA—malignant glioma	1.01e-06	3.65e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—MYC—malignant glioma	1.01e-06	3.64e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MMP9—malignant glioma	1.01e-06	3.64e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PPARG—malignant glioma	1e-06	3.62e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PTEN—malignant glioma	1e-06	3.62e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—AKT1—malignant glioma	9.98e-07	3.61e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—STAT3—malignant glioma	9.91e-07	3.58e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—VEGFA—malignant glioma	9.87e-07	3.57e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—FGF2—malignant glioma	9.87e-07	3.57e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—EGFR—malignant glioma	9.86e-07	3.56e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	9.84e-07	3.56e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—malignant glioma	9.84e-07	3.56e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—malignant glioma	9.79e-07	3.54e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—STAT3—malignant glioma	9.77e-07	3.53e-06	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—AKT1—malignant glioma	9.77e-07	3.53e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—AKT1—malignant glioma	9.76e-07	3.53e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—EGFR—malignant glioma	9.76e-07	3.53e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CXCL8—malignant glioma	9.75e-07	3.53e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—AKT1—malignant glioma	9.74e-07	3.52e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—GSTP1—malignant glioma	9.7e-07	3.51e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CD—malignant glioma	9.66e-07	3.49e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—VEGFA—malignant glioma	9.66e-07	3.49e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—malignant glioma	9.61e-07	3.48e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—PIK3CA—malignant glioma	9.57e-07	3.46e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—STAT3—malignant glioma	9.56e-07	3.46e-06	CbGpPWpGaD
Dasatinib—LYN—Immune System—AKT1—malignant glioma	9.53e-07	3.45e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—VEGFA—malignant glioma	9.51e-07	3.44e-06	CbGpPWpGaD
Dasatinib—ABL1—Immune System—AKT1—malignant glioma	9.49e-07	3.43e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAT—malignant glioma	9.44e-07	3.41e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—STAT3—malignant glioma	9.42e-07	3.41e-06	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—AKT1—malignant glioma	9.42e-07	3.41e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—BCHE—malignant glioma	9.41e-07	3.4e-06	CbGpPWpGaD
Dasatinib—FYN—Immune System—AKT1—malignant glioma	9.39e-07	3.39e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—CASP3—malignant glioma	9.33e-07	3.37e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—IL2—malignant glioma	9.32e-07	3.37e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—malignant glioma	9.31e-07	3.37e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—SLC5A5—malignant glioma	9.3e-07	3.36e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MDM2—malignant glioma	9.23e-07	3.34e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—malignant glioma	9.22e-07	3.33e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—MYC—malignant glioma	9.21e-07	3.33e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—RAF1—malignant glioma	9.2e-07	3.33e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—VEGFA—malignant glioma	9.16e-07	3.31e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CD—malignant glioma	9.13e-07	3.3e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—CAV1—malignant glioma	9.1e-07	3.29e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—ERBB2—malignant glioma	9.1e-07	3.29e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—MYC—malignant glioma	9.08e-07	3.28e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—STAT3—malignant glioma	9.07e-07	3.28e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—VEGFA—malignant glioma	9.04e-07	3.27e-06	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—AKT1—malignant glioma	9.04e-07	3.27e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—PIK3CA—malignant glioma	9.04e-07	3.27e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—EGFR—malignant glioma	9.01e-07	3.26e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—AKT1—malignant glioma	8.99e-07	3.25e-06	CbGpPWpGaD
Dasatinib—MAPK14—Gene Expression—AKT1—malignant glioma	8.99e-07	3.25e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CB—malignant glioma	8.98e-07	3.25e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—STAT3—malignant glioma	8.95e-07	3.24e-06	CbGpPWpGaD
Dasatinib—JAK2—Immune System—AKT1—malignant glioma	8.92e-07	3.23e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—NCOR1—malignant glioma	8.92e-07	3.22e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—MYC—malignant glioma	8.89e-07	3.21e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—EGFR—malignant glioma	8.88e-07	3.21e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—PIK3CA—malignant glioma	8.83e-07	3.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MMP9—malignant glioma	8.82e-07	3.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PTEN—malignant glioma	8.77e-07	3.17e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—MYC—malignant glioma	8.75e-07	3.16e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—malignant glioma	8.74e-07	3.16e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—EGFR—malignant glioma	8.69e-07	3.14e-06	CbGpPWpGaD
Dasatinib—FYN—Disease—AKT1—malignant glioma	8.67e-07	3.13e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CXCL8—malignant glioma	8.63e-07	3.12e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—EGFR—malignant glioma	8.56e-07	3.1e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—PIK3CA—malignant glioma	8.55e-07	3.09e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—malignant glioma	8.51e-07	3.08e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—PIK3CA—malignant glioma	8.47e-07	3.06e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—MYC—malignant glioma	8.43e-07	3.05e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CB—malignant glioma	8.42e-07	3.05e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—malignant glioma	8.39e-07	3.03e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTGS2—malignant glioma	8.34e-07	3.02e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—MYC—malignant glioma	8.32e-07	3.01e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CG—malignant glioma	8.29e-07	3e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—malignant glioma	8.28e-07	2.99e-06	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—AKT1—malignant glioma	8.27e-07	2.99e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—CASP3—malignant glioma	8.26e-07	2.99e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—IL2—malignant glioma	8.25e-07	2.98e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—EGFR—malignant glioma	8.24e-07	2.98e-06	CbGpPWpGaD
Dasatinib—JAK2—Disease—AKT1—malignant glioma	8.24e-07	2.98e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—malignant glioma	8.21e-07	2.97e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—EGFR—malignant glioma	8.14e-07	2.94e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—malignant glioma	8.09e-07	2.92e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PPARG—malignant glioma	8e-07	2.89e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CB—malignant glioma	7.96e-07	2.88e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—VEGFA—malignant glioma	7.92e-07	2.86e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTGS2—malignant glioma	7.88e-07	2.85e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—PIK3CA—malignant glioma	7.88e-07	2.85e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—STAT3—malignant glioma	7.84e-07	2.84e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—PIK3CA—malignant glioma	7.82e-07	2.83e-06	CbGpPWpGaD
Dasatinib—LCK—Immune System—AKT1—malignant glioma	7.81e-07	2.83e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MMP9—malignant glioma	7.81e-07	2.82e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—malignant glioma	7.79e-07	2.82e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PTEN—malignant glioma	7.76e-07	2.81e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—PIK3CA—malignant glioma	7.71e-07	2.79e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—malignant glioma	7.69e-07	2.78e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—PIK3CA—malignant glioma	7.54e-07	2.73e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—GSTP1—malignant glioma	7.49e-07	2.71e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—malignant glioma	7.46e-07	2.7e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—PIK3CA—malignant glioma	7.43e-07	2.69e-06	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—AKT1—malignant glioma	7.38e-07	2.67e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—malignant glioma	7.3e-07	2.64e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CD—malignant glioma	7.29e-07	2.64e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAT—malignant glioma	7.29e-07	2.64e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—MYC—malignant glioma	7.29e-07	2.63e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PTEN—malignant glioma	7.28e-07	2.63e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—CAV1—malignant glioma	7.27e-07	2.63e-06	CbGpPWpGaD
Dasatinib—LCK—Disease—AKT1—malignant glioma	7.21e-07	2.61e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—malignant glioma	7.19e-07	2.6e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—PIK3CA—malignant glioma	7.16e-07	2.59e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—PIK3CA—malignant glioma	7.15e-07	2.59e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—EGFR—malignant glioma	7.13e-07	2.58e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—PIK3CA—malignant glioma	7.06e-07	2.55e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—VEGFA—malignant glioma	7.01e-07	2.54e-06	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—AKT1—malignant glioma	6.99e-07	2.53e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	6.94e-07	2.51e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—STAT3—malignant glioma	6.94e-07	2.51e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—malignant glioma	6.92e-07	2.5e-06	CbGpPWpGaD
Dasatinib—SRC—Immune System—AKT1—malignant glioma	6.92e-07	2.5e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—NCOR1—malignant glioma	6.88e-07	2.49e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PTEN—malignant glioma	6.87e-07	2.49e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—malignant glioma	6.83e-07	2.47e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—malignant glioma	6.73e-07	2.43e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CG—malignant glioma	6.62e-07	2.39e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—MYC—malignant glioma	6.45e-07	2.33e-06	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—AKT1—malignant glioma	6.43e-07	2.33e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PPARG—malignant glioma	6.39e-07	2.31e-06	CbGpPWpGaD
Dasatinib—SRC—Disease—AKT1—malignant glioma	6.39e-07	2.31e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CB—malignant glioma	6.35e-07	2.3e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—EGFR—malignant glioma	6.31e-07	2.28e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTGS2—malignant glioma	6.3e-07	2.28e-06	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—AKT1—malignant glioma	6.3e-07	2.28e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—PIK3CA—malignant glioma	6.18e-07	2.24e-06	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—AKT1—malignant glioma	6.16e-07	2.23e-06	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—AKT1—malignant glioma	6.07e-07	2.19e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—malignant glioma	5.98e-07	2.16e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—malignant glioma	5.96e-07	2.16e-06	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—AKT1—malignant glioma	5.85e-07	2.12e-06	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—AKT1—malignant glioma	5.84e-07	2.11e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CD—malignant glioma	5.82e-07	2.1e-06	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—AKT1—malignant glioma	5.77e-07	2.09e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—CAV1—malignant glioma	5.61e-07	2.03e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PTEN—malignant glioma	5.49e-07	1.99e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—PIK3CA—malignant glioma	5.47e-07	1.98e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—malignant glioma	5.3e-07	1.92e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—PIK3CA—malignant glioma	5.13e-07	1.86e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CG—malignant glioma	5.11e-07	1.85e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CB—malignant glioma	5.07e-07	1.83e-06	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—AKT1—malignant glioma	5.05e-07	1.83e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTGS2—malignant glioma	5.03e-07	1.82e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PPARG—malignant glioma	4.93e-07	1.78e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—PIK3CA—malignant glioma	4.85e-07	1.75e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CD—malignant glioma	4.49e-07	1.62e-06	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—AKT1—malignant glioma	4.47e-07	1.62e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PTEN—malignant glioma	4.38e-07	1.59e-06	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—AKT1—malignant glioma	4.19e-07	1.52e-06	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—AKT1—malignant glioma	3.96e-07	1.43e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CB—malignant glioma	3.92e-07	1.42e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTGS2—malignant glioma	3.88e-07	1.4e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—PIK3CA—malignant glioma	3.87e-07	1.4e-06	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PTEN—malignant glioma	3.38e-07	1.22e-06	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—AKT1—malignant glioma	3.16e-07	1.14e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—PIK3CA—malignant glioma	3.09e-07	1.12e-06	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—AKT1—malignant glioma	2.53e-07	9.14e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—PIK3CA—malignant glioma	2.39e-07	8.63e-07	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—AKT1—malignant glioma	1.95e-07	7.05e-07	CbGpPWpGaD
